A.R.T. Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

A.R.T. Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-80,388	Closed	-$646K	–	1852
2018 Q2	$646K	Buy	80,388 +37,750	+89%	+$288K	0.03%	820
2018 Q1	$318K	Buy	+42,638	New	+$284K	0.01%	1113
2017 Q2	–	Sell	-15,600	Closed	-$147K	–	1867
2017 Q1	$147K	Buy	+15,600	New	+$156K	0.01%	1221
2016 Q4	–	Sell	-35,700	Closed	-$225K	–	1454
2016 Q3	$225K	Buy	+35,700	New	+$216K	0.07%	452
2016 Q2	–	Sell	-307,523	Closed	-$1.34M	–	1759
2016 Q1	$1.34M	Buy	307,523 +217,500	+242%	+$969K	0.06%	460
2015 Q4	$551K	Buy	+90,023	New	+$590K	0.03%	823
2015 Q3	–	Sell	-13,188	Closed	-$98K	–	1717
2015 Q2	$98K	Buy	+13,188	New	+$79.8K	﹤0.01%	1369

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

A.R.T. Advisors's PGNX Position: Q3 2018 in Review

A.R.T. Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 80,388 shares — an estimated $646K sold.

A.R.T. Advisors first reported a position in PGNX in Q2 2015 and held it in 7 quarters. The position peaked at $1.34M in Q1 2016. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

A.R.T. Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
A.R.T. Advisors sold 80,388 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $646K.
A.R.T. Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 7 quarters.
A.R.T. Advisors's Progenics Pharmaceuticals Inc position peaked at $1.34M in Q1 2016.
149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.